Medical Licensing (MD/DO) · Independent exam preparation
ABOG Specialty Qualifying Examination: Clinical Decision Guide Study Guide
Practise labor management, fetal surveillance, hypertensive emergencies, surgical complications, office medical care, contraception, and screening for ABOG's Specialty Qualifying Examination.
By CertMedbry · Updated 2 November 2026
Practise deciding when labor has arrested, when abnormal fetal monitoring requires delivery, when pelvic pain requires surgery, and which preventive or reproductive intervention fits an individual patient. This guide follows the three domains of ABOG's Specialty Qualifying Examination and uses clinical guidelines to support management decisions. Its 60 concepts are selective: the official Specialty Blueprint defines the full examination scope, including topics and cross-content skills beyond this collection. Equal domain counts do not imply proportional coverage of subtopics.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide address?
The pathway is initial ABOG specialty certification in obstetrics and gynecology: the written Specialty Qualifying Examination precedes the oral Specialty Certifying Examination. The latter includes clinical scenarios and review of practice case lists. This guide does not address a subspecialty examination.
2026 Specialty Qualifying Examination Bulletin · ABOG 2024 Annual Report, pages 33–34
Which blueprint and bulletin apply?
The specialty blueprint entered operational use in 2024 following the 2023 job-task analysis. The accompanying examination reference is the 2026 Specialty Qualifying Examination Bulletin, issued September 2025. An exact blueprint effective month and day is not established here. The separate 2026 subspecialty blueprint timeline should not be applied to this specialty examination.
ABOG 2025 Annual Report, page 49 · Specialty Blueprint · 2026 Specialty Qualifying Examination Bulletin
How is examination content weighted?
Obstetrics, Gynecology, and Office Practice each account for approximately 33%. These approximate figures total 99%; they do not establish another domain. The largest listed subtopics are intrapartum care, complications, and obstetrical procedures at 18%, and office management–gynecology at 15% of the whole examination. This guide uses 20 concepts per domain. Questions are distributed 7/7/6 and flashcards 7/6/7 across Obstetrics/Gynecology/Office Practice. These counts do not reproduce the examination's subtopic proportions.
How many questions are on the examination, and how many are scored?
The 2026 examination contains 230 single-best-answer multiple-choice questions. The scored-versus-pretest breakdown is not established by the evidence presented here. The 20 questions in this collection are an independent study set, not the official examination length.
What are the duration, testing location, and adaptivity?
The 2026 examination is scheduled for approximately 3 hours 45 minutes at Pearson VUE testing centers. The evidence presented here does not establish the detailed break structure or whether testing is adaptive. Consult the applicable candidate instructions for those remaining operational details.
Which item styles does this practice set use?
The official 2026 examination uses single-best-answer multiple-choice questions. This collection uses original four-option questions in that format, with explanations of the best answer and each alternative. These independent drills teach clinical reasoning and do not reproduce the oral Certifying Examination or predict a passing result.
2026 Specialty Qualifying Examination Bulletin · ABOG 2024 Annual Report, pages 33–34
Does this guide cover the entire official outline?
No. The official Specialty Blueprint defines the full scope. It includes additional maternal disease, fetal assessment, operative procedures, menstrual and endocrine disorders, menopause, abortion, cancers, and office procedures. Cross-content also includes basic science, statistics, evidence-based medicine, equitable care, communication, error disclosure, handoffs, teamwork, quality improvement, and professionalism. Use this selective guide alongside that outline.
This guide addresses ABOG's initial written Specialty Qualifying Examination in obstetrics and gynecology. Specialty certification is voluntary and distinct from state medical licensure. The later oral Specialty Certifying Examination and separate subspecialty examinations have different purposes and requirements. These independently authored learning materials are not official ABOG examination items.
Outline used: 2024 Specialty Blueprint, operational beginning in 2024; 2026 Specialty Qualifying Examination Bulletin, issued September 2025. The assigned workbook label maps to ABOG’s Specialty Qualifying Examination in obstetrics and gynecology. No newer specialty qualifying blueprint was identified in the issuer-focused search conducted for the 2026-11-02 review.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Obstetricsapproximately 33%
1.When should folic acid supplementation begin?
Neural tube closure occurs early, often before pregnancy is recognized, so prevention must begin before conception. The USPSTF recommends a daily supplement containing 0.4–0.8 mg of folic acid for people planning pregnancy or capable of becoming pregnant, beginning at least one month before conception and continuing through the first two to three months of pregnancy. This average-risk recommendation does not define management for a previous neural tube defect–affected pregnancy or other high-risk circumstances.
Apply it
A patient stopping contraception next month asks whether supplementation can wait until the first prenatal appointment. Recommend beginning a daily supplement now, explaining that the developmental window for neural tube prevention precedes many first pregnancy visits.
Common pitfall: Waiting for a positive pregnancy test can miss part of the preventive window. Do not apply the average-risk dose automatically to a patient with a previously affected pregnancy.
USPSTF: Folic Acid Supplementation to Prevent Neural Tube Defects
2.Which patients warrant aspirin prophylaxis for preeclampsia?
The USPSTF recommends low-dose aspirin, 81 mg daily after 12 weeks of gestation, for pregnant patients at high risk of preeclampsia. High-risk factors include previous preeclampsia, multifetal gestation, chronic hypertension, pregestational diabetes, kidney disease, and autoimmune disease. Combinations of moderate-risk factors can also justify prophylaxis. Aspirin reduces the likelihood of preeclampsia-related morbidity; it does not treat established severe hypertension or replace surveillance for maternal and fetal complications.
Apply it
At 13 weeks, a patient with chronic hypertension has no headache, proteinuria, or laboratory abnormalities. Her existing hypertension still establishes high risk, making preventive low-dose aspirin appropriate despite the absence of current preeclampsia findings.
Common pitfall: Do not wait for proteinuria before considering prophylaxis. Conversely, aspirin is not an acute treatment for a patient already presenting with severe hypertensive disease.
USPSTF: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
3.When is routine gestational diabetes screening supported?
Pregnancy-associated insulin resistance can reveal inadequate pancreatic compensation and produce gestational diabetes. The USPSTF recommends screening asymptomatic pregnant patients at 24 weeks of gestation or later. Its evidence assessment for routine screening before 24 weeks is insufficient, which is different from recommending against testing for suspected preexisting diabetes. Distinguish routine population screening from diagnostic evaluation prompted by symptoms, marked hyperglycemia, or concern that diabetes predates pregnancy.
Apply it
An asymptomatic patient without known diabetes presents at 25 weeks after missing an earlier prenatal visit. Arrange gestational diabetes screening now; the recommended screening window remains applicable even though no testing occurred during the first trimester.
Common pitfall: An insufficient-evidence statement about early routine screening does not mean symptomatic hyperglycemia should be ignored or that known pregestational diabetes should be relabeled as gestational diabetes.
4.When does a short cervix support vaginal progesterone rather than routine cerclage?
SMFM recommends transvaginal cervical measurement for treatment decisions and defines a short cervix as 25 mm or less in a singleton pregnancy without previous spontaneous preterm birth. Vaginal progesterone is recommended for a cervical length of 20 mm or less before 24 weeks; at 21–25 mm, shared decision making is appropriate. In this population, cerclage is not recommended for a cervical length of 10–25 mm when dilation is absent. Physical examination–detected dilation requires a separate assessment.
Apply it
A patient with a singleton pregnancy, no prior spontaneous preterm birth, and a closed cervix has a transvaginal cervical length of 18 mm at 21 weeks. Recommend vaginal progesterone; shortening alone does not establish a routine cerclage indication.
Common pitfall: Do not substitute an imprecise transabdominal estimate for standardized transvaginal measurement or transfer these recommendations automatically to twin pregnancies or a dilated cervix.
SMFM Consult Series No. 70: Management of Short Cervix Without Previous Spontaneous Preterm Birth
5.When does severe hypertension in pregnancy require emergency treatment?
Systolic pressure of at least 160 mm Hg or diastolic pressure of at least 110 mm Hg persisting for 15 minutes requires urgent antihypertensive treatment during pregnancy or postpartum. Begin treatment as soon as possible, within 30–60 minutes of confirmation, to reduce stroke risk. First-line options include intravenous labetalol, intravenous hydralazine, or immediate-release oral nifedipine, particularly without intravenous access. Magnesium sulfate prevents or treats eclamptic seizures; it does not replace blood-pressure treatment. See [ACOG Practice Bulletin 222](https://www.preeclampsia.org/frontend/assets/img/advocacy_resource/Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin%2C_Number_222_1605448006.pdf) and [ACOG Committee Opinion 767](https://pubmed.ncbi.nlm.nih.gov/30575639/).
Apply it
At 35 weeks, repeated pressures remain 168/112 mm Hg over 15 minutes. Start emergency treatment while assessing maternal organ involvement and fetal status; do not wait for a four-hour interval or proteinuria results.
Common pitfall: Either severe systolic or severe diastolic pressure qualifies. Aspirin prophylaxis and magnesium sulfate cannot substitute for acute antihypertensive therapy.
6.How do umbilical artery Doppler findings change growth-restriction management?
SMFM defines fetal growth restriction as estimated fetal weight or abdominal circumference below the 10th percentile. Obtain umbilical artery Doppler assessments every one to two weeks after diagnosis and weekly cardiotocography after viability when absent or reversed flow is not present. Estimated fetal weight between the third and 10th percentiles with normal Doppler supports delivery at 38–39 weeks. Decreased end-diastolic flow, reflected by flow ratios above the 95th percentile but without absent or reversed flow, warrants weekly Doppler assessment and delivery at 37 weeks. Estimated fetal weight below the third percentile also warrants weekly Doppler assessment and delivery at 37 weeks, even with normal flow. Absent end-diastolic flow warrants Doppler assessment two to three times weekly and delivery at 33–34 weeks. Reversed flow warrants hospitalization, corticosteroids, cardiotocography at least once or twice daily, and delivery at 30–32 weeks.
Apply it
At 35 weeks, a fetus at the seventh percentile with decreased but still forward end-diastolic flow generally follows the 37-week delivery pathway. A fetus at the second percentile with normal Doppler also follows the 37-week pathway. At 31 weeks, reversed flow instead requires hospitalization, corticosteroids, intensified surveillance, and delivery within the 30–32-week range.
Common pitfall: Distinguish decreased forward flow from absent flow and reversed flow; they have different surveillance intensity and delivery windows. The 38–39-week recommendation applies to estimated weight between the third and 10th percentiles with normal Doppler. Maternal or fetal deterioration can require delivery earlier than the scheduled window.
SMFM Consult Series No. 52: Diagnosis and Management of Fetal Growth Restriction
7.Why are corticosteroids and magnesium different before preterm delivery?
Antenatal corticosteroids and magnesium sulfate address different neonatal risks when preterm delivery is anticipated. Corticosteroids promote fetal maturation and reduce complications associated with prematurity. Magnesium sulfate is used for fetal neuroprotection when delivery before 32 weeks is likely under SMFM guidance. Neither medication repairs placental insufficiency or guarantees that delivery can be postponed. Their use should accompany, rather than replace, assessment of whether maternal or fetal deterioration requires delivery.
Apply it
At 29 weeks, worsening growth-restriction surveillance makes delivery likely soon. Consider both antenatal corticosteroids and magnesium sulfate, explaining that the former supports maturation while the latter targets neurologic protection rather than fetal growth or placental blood flow.
Common pitfall: Do not describe magnesium as a substitute for corticosteroids. Completing a medication course must not override a compelling indication for urgent maternal or fetal intervention.
SMFM Consult Series No. 52: Diagnosis and Management of Fetal Growth Restriction
8.When should active-phase labor standards begin?
ACOG places the beginning of the active phase at 6 cm of cervical dilation. Before that point, slow progress may represent the latent phase rather than active-phase arrest. This distinction matters because applying active-phase time limits too early can lead to unnecessary cesarean delivery. Evaluate maternal status, fetal status, contractions, membrane status, and cervical change together. A prolonged latent phase alone does not establish active-phase arrest when mother and fetus remain reassuring.
Apply it
A nulliparous patient remains at 5 cm for several hours but has reassuring fetal monitoring and stable vital signs. Continue evaluating and supporting labor instead of diagnosing active-phase arrest solely from the time spent at that dilation.
Common pitfall: Older expectations of rapid dilation beginning at 4 cm can misclassify normal variation. Reaching a time threshold is meaningful only within the correct labor phase.
ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management
9.Which findings establish active-phase arrest, and how is contraction adequacy measured?
ACOG defines active-phase arrest as no cervical progression at 6 cm or more with ruptured membranes despite four hours of adequate uterine activity or six hours of inadequate activity with oxytocin augmentation. When indicated, an intrauterine pressure catheter quantifies activity: Montevideo units are the sum of contraction amplitudes above baseline pressure over 10 minutes. Approximately 200 MVU is the conventional adequacy threshold. External monitoring measures contraction frequency and duration but does not reliably quantify contraction strength. Clinical deterioration can require intervention before arrest criteria are completed.
Apply it
At 7 cm with ruptured membranes, five contractions rise 45 mm Hg above baseline during 10 minutes, totaling 225 MVU. Four hours without cervical change despite this adequate activity supports active-phase arrest. Five contractions seen externally would not establish the same quantitative adequacy.
Common pitfall: Do not infer adequate pressure from frequency alone. Apply the longer six-hour interval when activity remains inadequate despite oxytocin, and count time only after the relevant prerequisites are met.
ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management
10.When can an induction reasonably be called unsuccessful?
Failure to enter active labor during induction differs from active-phase arrest after reaching at least 6 cm. When maternal and fetal status permit, ACOG recommends administering oxytocin for at least 12–18 hours after membrane rupture before considering an induction unsuccessful during the latent phase. Cervical ripening time alone is not equivalent to this interval. The purpose is to allow adequate opportunity for labor to develop while continuing to assess safety and response.
Apply it
After overnight cervical ripening, a stable patient has received only four hours of oxytocin following membrane rupture and remains at 4 cm. The elapsed ripening time does not establish failed induction; continue appropriate induction management while reassessing status.
Common pitfall: Do not substitute total hospital time for the relevant oxytocin-after-rupture interval. These recommendations assume continued maternal and fetal stability, not an obligation to delay necessary delivery.
ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management
11.How should prolonged second-stage pushing be interpreted?
ACOG defines prolonged second stage as more than three hours of pushing in nulliparous patients or two hours in multiparous patients. These thresholds prompt individualized assessment rather than automatic operative delivery. Consider descent, rotation, contraction quality, maternal condition, fetal status, and the likelihood of vaginal birth. Arrest can be recognized earlier when there is no rotation or descent despite adequate contractions and pushing. Distinguish active pushing time from the entire period after complete dilation.
Apply it
A nulliparous patient has pushed for just over three hours with continued descent and reassuring fetal status. Discuss the evolving likelihood of vaginal delivery and available interventions rather than treating the time threshold alone as an absolute cesarean indication.
Common pitfall: A clock cannot replace assessment of descent and rotation. Conversely, a patient need not exhaust a time allowance when persistent absent progress or clinical deterioration changes the decision.
ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management
12.When should operative vaginal delivery be considered?
For selected patients with second-stage arrest, ACOG recommends assessing whether operative vaginal delivery is appropriate before proceeding to cesarean delivery. A safe attempt requires an accurately identified fetal head position, adequate descent, complete dilation, ruptured membranes, and an appropriately skilled clinician. The decision also depends on the clinical indication and ability to perform cesarean delivery if needed. An instrument does not overcome an uncertain position, an unengaged head, or absent operator competence.
Apply it
A fully dilated patient has a low, engaged fetal head in a clearly established position and exhausted pushing. An experienced operator can evaluate an assisted vaginal birth as an alternative to immediate second-stage cesarean delivery after appropriate discussion.
Common pitfall: Do not treat operative vaginal delivery as a mandatory intermediate step. Uncertain position, unsuitable station, or insufficient expertise can make cesarean delivery the safer option.
ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management
13.How should placenta accreta spectrum risk change delivery planning?
Placenta accreta spectrum involves abnormal placental adherence or invasion and can cause catastrophic hemorrhage during attempted separation. Previous cesarean delivery is an important risk factor, especially with placenta previa over the scar region; absent ultrasound findings do not exclude the disorder. ACOG–SMFM guidance supports multidisciplinary planning with hemorrhage resources. The generally accepted operative approach is cesarean hysterectomy with the placenta left in situ after fetal delivery. Conservative approaches require individualized counseling and are not equivalent to routine manual removal.
Apply it
A patient with several previous cesarean deliveries and persistent previa has equivocal imaging. Maintain suspicion and coordinate expert delivery planning. During planned cesarean hysterectomy, deliver away from the placenta and leave it undisturbed.
Common pitfall: An uncertain scan cannot erase a strong clinical risk pattern. Applying traction to test placental adherence can itself precipitate hemorrhage.
ACOG–SMFM Obstetric Care Consensus No. 7: Placenta Accreta Spectrum
14.How should a category III fetal heart-rate tracing change intrapartum management?
Category III includes absent baseline variability with recurrent late decelerations, recurrent variable decelerations, or bradycardia, or a sinusoidal pattern. Promptly evaluate and address reversible causes: reposition the patient, stop oxytocin, treat maternal hypotension, and address tachysystole. If a category III tracing persists despite appropriate initial resuscitation, expedite delivery by the safest feasible route. Routine oxygen is not recommended without maternal hypoxia. Category II requires evaluation and repeated assessment, rather than automatic classification as category III. See [ACOG Clinical Practice Guideline 10](https://obgyn.wustl.edu/app/uploads/2025/09/acog_clinical_practice_guideline_no_.22.pdf).
Apply it
Oxytocin-associated tachysystole accompanies absent variability and recurrent late decelerations. Stop oxytocin and begin corrective measures while preparing for delivery if the tracing fails to recover; do not wait for labor-arrest criteria.
Common pitfall: Recurrent late decelerations with moderate variability are category II, not category III. Persistent category III findings require action independent of cervical progress.
15.How should postpartum hemorrhage treatment address its cause?
Postpartum hemorrhage requires concurrent resuscitation and identification of the bleeding mechanism. Uterine atony, genital tract trauma, retained placental tissue, and coagulation abnormalities require different source-control measures and may coexist. The WHO approach combines uterine assessment and massage, an oxytocic agent, tranexamic acid, intravenous fluids, examination, and escalation as indicated. A firm uterus with continued bleeding should prompt assessment for trauma or another cause rather than repeated reliance on uterotonics alone.
Apply it
After vaginal birth, brisk bleeding continues despite a firm, contracted uterus. While resuscitation proceeds, inspect for genital tract injury and assess other sources instead of assuming every postpartum hemorrhage represents persistent atony requiring additional uterotonic treatment.
Common pitfall: Sequentially trying one treatment at a time can delay control of major bleeding. A single identified cause does not exclude an accompanying laceration or coagulation problem.
16.Why should tranexamic acid be given early in postpartum hemorrhage?
Tranexamic acid is an antifibrinolytic: it limits breakdown of fibrin clots rather than causing uterine contraction. WHO recommends early intravenous administration within three hours of birth for postpartum hemorrhage, alongside standard treatment. Its mechanism makes it complementary to uterotonics and source control, including treatment of traumatic bleeding. It does not repair a laceration, remove retained tissue, or replace blood-volume support. Recognition and administration should therefore occur within an organized hemorrhage response.
Apply it
A patient develops major bleeding shortly after birth despite initial uterine massage and oxytocin. Add early tranexamic acid while the team continues resuscitation and identifies the source, recognizing that clot stabilization and uterine contraction address different mechanisms.
Common pitfall: Do not reserve tranexamic acid until every other intervention has failed. Calling it a uterotonic obscures why it remains useful alongside contraction-directed treatment and surgical control.
WHO: Bleeding After Birth—Provider Guide · DailyMed - TRANEXAMIC ACID injection, solution
17.How should penicillin allergy affect syphilis treatment in pregnancy?
Penicillin G is the only known effective antimicrobial for treating fetal infection and preventing congenital syphilis. CDC guidance therefore recommends desensitization followed by penicillin treatment when a pregnant patient with syphilis has a penicillin allergy. The regimen must match the infection stage. An apparently convenient alternative antibiotic cannot be assumed to protect the fetus. Treatment is directed at both maternal disease and fetal risk, making pregnancy a decisive modifier of antibiotic selection.
Apply it
A pregnant patient with confirmed syphilis reports a previous immediate allergic reaction to penicillin. Arrange evaluation and desensitization so she can receive stage-appropriate penicillin rather than substituting an antibiotic selected only for maternal tolerability.
Common pitfall: Do not interpret treatment of maternal symptoms as proof of fetal protection. Penicillin allergy changes how treatment is delivered, not the need for effective penicillin therapy.
18.When is intrapartum group B streptococcal prophylaxis needed?
ACOG recommends vaginal–rectal group B streptococcal screening at 36 0/7–37 6/7 weeks. A positive culture generally indicates intrapartum prophylaxis because neonatal exposure occurs during labor or after membrane rupture. An important exception is cesarean delivery performed before labor with intact membranes, when GBS-specific prophylaxis is unnecessary regardless of the culture result. This exception does not remove the separate indication for routine cesarean surgical prophylaxis. Obstetric interventions should not be delayed solely to complete antibiotic exposure.
Apply it
A patient with a positive prenatal GBS culture arrives for scheduled cesarean delivery without contractions and with intact membranes. Give indicated surgical prophylaxis, but recognize that the positive culture alone does not require additional GBS-specific intrapartum prophylaxis.
Common pitfall: Do not generalize the prelabor cesarean exception to a patient already in labor or with ruptured membranes. Surgical prophylaxis and neonatal GBS prevention answer different clinical questions.
ACOG Committee Opinion No. 797: Prevention of Group B Streptococcal Early-Onset Disease in Newborns
19.Who receives postpartum Rh(D) immune globulin?
Postpartum Rh(D) immune globulin provides passive anti-D to prevent an unsensitized Rh-negative mother from developing an immune response to Rh-positive fetal erythrocytes. When the newborn is Rh-positive, it is administered to the mother, ordinarily within 72 hours of delivery. Assessment of fetomaternal hemorrhage can identify a need for additional protection beyond the standard dose. It prevents future alloimmunization; it does not reverse established maternal anti-D sensitization or treat neonatal hemolysis.
Apply it
An unsensitized Rh-negative patient delivers an Rh-positive infant. Arrange maternal postpartum Rh(D) immune globulin and assess whether the amount of fetomaternal hemorrhage requires additional dosing; the newborn is not the recipient of this preventive injection.
Common pitfall: A prenatal dose does not automatically replace postpartum prophylaxis. Distinguish prevention in an unsensitized mother from management of a pregnancy already complicated by immune anti-D.
20.When is lactational amenorrhea a contraceptive method?
The lactational amenorrhea method requires three simultaneous conditions: amenorrhea, full or nearly full breastfeeding, and less than six months postpartum. Feeding intervals must not exceed four hours during the day or six hours at night. Return of menstruation, longer feeding gaps, substantial supplementation, or reaching six months means the criteria are no longer all satisfied. Discuss another method before a predictable transition makes pregnancy prevention unreliable.
Apply it
A patient four months postpartum remains amenorrheic and breastfeeds frequently during the day, but the infant routinely sleeps eight hours without feeding. The nighttime interval exceeds the method's criteria; help her start another contraceptive method.
Common pitfall: Breastfeeding and amenorrhea alone are insufficient. Long feeding gaps can invalidate eligibility even when the patient describes herself as exclusively breastfeeding.
Gynecologyapproximately 33%
21.What makes surgical consent an informed decision?
Informed consent requires understandable information, decision-making capacity, voluntary choice, and an opportunity to weigh reasonable alternatives, including declining treatment. ACOG describes consent as an ongoing communication process rather than merely a signed document. Discuss the procedure's purpose, material risks, expected benefits, and alternatives in relation to the patient's goals. A patient who understands the consequences may refuse a recommended operation; disagreement with the clinician does not itself establish incapacity.
Apply it
A patient can explain the expected benefits and risks of hysterectomy but prefers to continue a reasonable nonsurgical option. Explore her priorities and document the informed choice rather than treating refusal as evidence that she cannot decide.
Common pitfall: A signature does not repair an incomprehensible or coercive discussion. Do not infer incapacity solely because a capable patient assigns different importance to outcomes than the clinician.
ACOG Committee Opinion No. 819: Informed Consent and Shared Decision Making
22.Which route is preferred for feasible benign hysterectomy?
ACOG recommends a minimally invasive route whenever feasible and prefers vaginal hysterectomy among minimally invasive approaches for benign disease. Route selection depends on uterine and vaginal anatomy, accessibility, extrauterine disease, concurrent procedures, surgeon experience, and patient preferences. When vaginal hysterectomy is unsuitable, laparoscopic surgery is generally preferable to an open abdominal approach when feasible. The choice should explain why the route fits the actual anatomy and operative needs rather than defaulting to a familiar technique.
Apply it
A patient needs hysterectomy for benign disease, has good vaginal access and uterine mobility, and requires no additional procedure that changes feasibility. Discuss vaginal hysterectomy as the preferred route while incorporating her informed preferences and the surgeon's expertise.
Common pitfall: Do not select an abdominal incision solely from habit or assume laparoscopic equipment makes that route preferable to an equally feasible vaginal procedure in benign disease.
ACOG Committee Opinion No. 701: Choosing the Route of Hysterectomy for Benign Disease
23.When should cefazolin prophylaxis begin before incision?
Surgical prophylaxis works by establishing effective antimicrobial concentrations in tissue when contamination can occur at incision. Joint ASHP/IDSA/SIS/SHEA guidance recommends beginning cefazolin within 60 minutes before incision for procedures in which it is indicated. Agents requiring longer infusions, such as vancomycin, have a longer preincision window. Match the drug, procedure, allergy assessment, and timing rather than treating every prophylactic antibiotic identically. Antibiotics given only after closure miss the intended preventive exposure.
Apply it
A hysterectomy is scheduled to begin at 10:00, and cefazolin is the selected prophylactic agent. Arrange administration within the preceding hour so effective tissue exposure is present at incision rather than waiting until the operation is underway.
Common pitfall: Do not confuse prophylaxis timing with treatment of an established infection. Applying cefazolin's window to a drug needing a prolonged infusion can produce inappropriate administration timing.
ASHP/IDSA/SIS/SHEA: Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery
24.Why should routine prophylaxis stop after surgical closure?
CDC guidance recommends against additional prophylactic antimicrobial doses after incision closure in clean and clean-contaminated operations, even when a drain is present. Prophylaxis protects during operative contamination; indefinite postoperative exposure does not become more effective simply because the patient remains hospitalized. Distinguish this recommendation from appropriate intraoperative redosing and from treatment of an established infection. Fever, purulence, or another postoperative concern requires diagnostic assessment rather than automatic extension of a prophylactic regimen.
Apply it
After an uncomplicated clean-contaminated gynecologic operation, a drain remains in place but there is no evidence of infection. Stop routine prophylaxis after closure rather than continuing antibiotics until the drain is removed or the patient leaves hospital.
Common pitfall: A drain is not an independent reason to prolong prophylaxis. Conversely, stopping prophylaxis does not mean withholding a separately indicated treatment course for a diagnosed infection.
CDC Guideline for the Prevention of Surgical Site Infection, 2017
25.How does multimodal analgesia support enhanced recovery?
Enhanced recovery pathways combine interventions that reduce surgical stress and support return of function. Multimodal analgesia uses complementary approaches so pain can be controlled while reducing reliance on opioids and their adverse effects. ACOG emphasizes that enhanced recovery is a coordinated perioperative pathway, not one medication or an instruction to discharge early. Analgesia should support breathing, mobilization, oral intake, and participation in recovery while remaining individualized to contraindications and the patient's operation.
Apply it
A patient after hysterectomy has pain that prevents walking and nausea after repeated opioid doses. Reassess the analgesic plan and incorporate appropriate complementary measures so symptom control supports movement and eating rather than simply increasing opioid exposure.
Common pitfall: Opioid reduction is not a reason to leave pain untreated. A pathway succeeds when function improves safely, not when a medication target replaces individualized assessment.
ACOG Committee Opinion No. 750: Perioperative Pathways—Enhanced Recovery After Surgery
26.Why do early feeding and mobilization matter after surgery?
Enhanced recovery counters avoidable postoperative inactivity and prolonged fasting through coordinated measures such as early mobilization and appropriate oral intake. These strategies support function and reduce the burden of conventional recovery practices when no complication requires restriction. Their value depends on the overall clinical course, adequate analgesia, and management of nausea. Persistent vomiting, hemodynamic instability, or concern for an operative complication should prompt reassessment rather than rigid continuation of a standard pathway.
Apply it
Following uncomplicated minimally invasive surgery, a stable patient has controlled nausea and wants to drink and walk. Support appropriate intake and assisted mobilization rather than requiring prolonged bed rest and fasting solely because surgery occurred earlier that day.
Common pitfall: Routine milestones do not override a new warning sign. Early feeding means appropriate progression in a suitable patient, not forcing intake despite persistent vomiting or suspected obstruction.
ACOG Committee Opinion No. 750: Perioperative Pathways—Enhanced Recovery After Surgery
27.How should a recognized ureteral injury be addressed?
An intraoperatively recognized ureteral injury should be assessed promptly and repaired when feasible, with experienced urologic involvement as needed. EAU guidance bases reconstruction on location, extent, tissue viability, and the ability to achieve a tension-free repair with preserved blood supply. A partial injury, transection, and devascularized thermal segment are not interchangeable problems. Recognition during the operation creates an opportunity for definitive management before urinary leakage, obstruction, infection, or renal impairment develops.
Apply it
During pelvic surgery, the team identifies a ureteral transection before closure. Obtain appropriate expertise, define the injury, and plan immediate repair when feasible rather than closing the operation with observation alone because the patient is currently stable.
Common pitfall: A stable blood pressure does not make a structural ureteral injury harmless. Do not assume that a stent alone can correct every transection or devascularized segment.
28.Which imaging evaluates a delayed postoperative ureteral injury?
Delayed ureteral injury may present with flank pain, fever, urinary leakage, obstruction, or an unexplained postoperative fluid collection. EAU guidance identifies CT urography, including delayed excretory-phase imaging, as the examination of choice when ureteral injury is suspected. The delayed phase helps demonstrate urinary extravasation or impaired drainage that a routine contrast-enhanced scan can miss. Normal serum creatinine does not reliably exclude a unilateral injury because the contralateral kidney may preserve overall filtration.
Apply it
Several days after hysterectomy, a patient develops unilateral flank pain and a pelvic fluid collection despite a near-baseline creatinine. Request CT urography with delayed images to evaluate the ureter rather than considering the normal creatinine sufficient reassurance.
Common pitfall: A routine abdominal CT without an excretory phase may not answer the urinary-leak question. Global renal function can remain deceptively normal with a unilateral ureteral injury.
29.How should a suspected postoperative bladder leak be imaged?
A suspected bladder injury requires imaging that distends the bladder sufficiently to reveal leakage. EAU guidance recommends cystography using active retrograde filling, performed with conventional radiography or CT. Passive accumulation of intravenously excreted contrast in the bladder is not an adequate substitute because underfilling can conceal a defect. The diagnostic question differs from suspected ureteral injury: cystography evaluates bladder integrity, whereas excretory-phase urography evaluates the upper urinary tract and ureters.
Apply it
After pelvic surgery, urinary drainage from an unexpected site raises concern for bladder leakage. Arrange adequately filled retrograde cystography rather than assuming a routine CT showing a little contrast in the bladder has excluded an operative defect.
Common pitfall: The presence of bladder contrast does not prove adequate distension. Selecting the wrong contrast route can produce false reassurance even when the scanner itself is appropriate.
30.How do hysteroscopic fluid type and deficit determine safety decisions?
Absorbed hypotonic, electrolyte-free medium can cause dilutional hyponatremia, hypo-osmolality, and neurologic deterioration. Isotonic saline can cause hypervolemia and pulmonary edema despite normal sodium. For otherwise healthy patients, BSGE/ESGE maximum deficit limits are 1,000 mL for hypotonic media and 2,500 mL for isotonic media, at which surgery should stop. Use lower limits with reduced cardiovascular or renal tolerance. Agree on limits beforehand and monitor cumulative deficit continuously; symptoms or rapid absorption can require stopping earlier.
Apply it
Confusion during hypotonic-media hysteroscopy requires stopping exposure and urgent sodium and fluid assessment. Hypoxemia with crackles during saline hysteroscopy suggests overload even with normal sodium. A healthy patient's saline deficit reaching 2,500 mL requires stopping even without symptoms.
Common pitfall: The published limits are ceilings, not targets. Normal sodium cannot exclude saline-related pulmonary edema, and the isotonic ceiling must not be applied to hypotonic media.
BSGE/ESGE Guideline on Management of Fluid Distension Media in Operative Hysteroscopy
31.Which postoperative symptoms should raise concern for bowel injury?
Increasing abdominal pain after laparoscopy, especially with fever, loss of appetite, and vomiting, can indicate bowel or bladder injury and warrants urgent hospital assessment. Recovery should generally improve; worsening symptoms should not be managed solely by escalating analgesia or attributing them to routine postoperative discomfort. An initially uncomplicated operation does not exclude a subsequently apparent injury. See [RCOG: Laparoscopy—recovering well](https://www-preview.rcog.org.uk/for-the-public/browse-our-patient-information/laparoscopy-recovering-well/).
Apply it
Three days after laparoscopic surgery, a patient reports worsening abdominal pain, fever, and vomiting. Arrange urgent hospital evaluation for an operative complication rather than advising another day of home observation.
Common pitfall: Expected transient postoperative discomfort should improve. Fever and worsening pain with impaired oral intake require reassessment even after an initially reassuring discharge.
32.How does postvoid residual change interpretation of postoperative leakage?
Urine leakage does not prove normal bladder emptying. An elevated postvoid residual identifies incomplete emptying and can accompany overflow symptoms, including frequent small voids or dribbling. EAU guidance supports measuring residual volume in the assessment of lower urinary tract symptoms, preferably by ultrasound. After pelvic surgery, interpret the measurement alongside voided volume, symptoms, medications, and the operative context. The residual establishes an emptying problem but does not alone identify whether obstruction or impaired detrusor contraction is responsible.
Apply it
After pelvic surgery, a patient reports frequent small voids and continuous dribbling. A substantial postvoid residual redirects assessment toward incomplete emptying, rather than treating the leakage immediately as uncomplicated urgency incontinence with medication that could worsen retention.
Common pitfall: Do not assume that passing some urine excludes retention. A residual measurement describes emptying performance; it does not by itself distinguish every underlying mechanism or establish one universal treatment.
EAU Guidelines on Non-neurogenic Female Lower Urinary Tract Symptoms: Diagnosis
33.When should postoperative symptoms trigger evaluation for venous thromboembolism?
A painful swollen leg suggests deep-vein thrombosis; sudden dyspnea, pleuritic chest pain, tachycardia, hypoxemia, syncope, or shock can indicate pulmonary embolism. Recent surgery and immobility increase risk. These findings require urgent assessment, with immediate stabilization when unstable. CT pulmonary angiography commonly evaluates suspected pulmonary embolism; a ventilation-perfusion scan may be appropriate when CT contrast is unsuitable. See [American Heart Association: Pulmonary Embolism](https://www.heart.org/en/health-topics/pulmonary-embolism).
Apply it
After hysterectomy, a patient develops sudden shortness of breath, pleuritic pain, and tachycardia. Escalate urgently for pulmonary embolism assessment instead of attributing the symptoms to postoperative inactivity without evaluation.
Common pitfall: Early mobilization supports recovery but does not exclude thromboembolism. New cardiopulmonary symptoms require a diagnostic decision, not simply reinforcement of routine recovery instructions.
34.When does suspected ectopic pregnancy require urgent surgery?
A suspected tubal ectopic pregnancy with hemodynamic instability or signs of rupture requires urgent surgical management. In this setting, intraperitoneal bleeding threatens circulation, and treatment cannot wait for serial hormone measurements or an elective medical regimen. ACOG distinguishes this emergency from carefully selected stable cases that may be managed medically. The decisive cues are the patient's physiologic condition and evidence of hemorrhage, not whether a particular human chorionic gonadotropin threshold has been reached.
Apply it
A patient with a positive pregnancy test develops severe pelvic pain, hypotension, tachycardia, and substantial free intraperitoneal fluid. Begin resuscitation and urgent surgical management instead of waiting for another quantitative hormone result to confirm the diagnosis.
Common pitfall: A low or declining pregnancy hormone level does not make suspected rupture safe for observation. Methotrexate cannot provide immediate control of life-threatening intraperitoneal bleeding.
ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy · Ectopic-Pregnancy-ACOG.pdf
35.Who can receive methotrexate for ectopic pregnancy, and how is response monitored?
Candidates must be stable with an unruptured ectopic pregnancy, no viable intrauterine pregnancy, and reliable follow-up. Exclusions include breastfeeding, clinically important renal or hepatic dysfunction, significant anemia, leukopenia or thrombocytopenia, and inability to follow up. Baseline evaluation includes quantitative hCG, blood count, renal and hepatic assessment, and ultrasound. In the single-dose protocol, give methotrexate 50 mg/m² intramuscularly on day 1 and measure hCG on days 4 and 7. A decline of at least 15% from day 4 to day 7 supports weekly monitoring to nonpregnant levels; inadequate decline requires reassessment for additional methotrexate or surgery.
Apply it
Day-4 hCG is 2,000 mIU/mL and day-7 hCG is 1,600 mIU/mL: the 20% decline supports weekly monitoring if clinically stable. A fall to 1,800 represents only 10% and requires reassessment for additional treatment.
Common pitfall: An early hCG rise before day 4 does not by itself establish failure. Adequate biochemical decline does not eliminate rupture risk; new severe pain, syncope, or instability requires urgent assessment.
36.How should pregnancy of unknown location be approached?
A positive pregnancy test without a definitively located pregnancy is a pregnancy of unknown location, not an automatic diagnosis of ectopic pregnancy. A stable patient may need serial quantitative human chorionic gonadotropin measurements and repeat transvaginal ultrasonography to clarify location and viability. A single hormone value or nondiagnostic scan cannot reliably settle both questions. ACOG's ectopic-pregnancy framework emphasizes accurate diagnosis because unnecessary methotrexate can harm an early intrauterine pregnancy that has not yet become visible.
Apply it
A stable patient with a desired early pregnancy has a nondiagnostic transvaginal ultrasound and uncertain dates. Arrange serial assessment and clear emergency precautions rather than treating the absent visible gestational sac as sufficient proof of an ectopic pregnancy.
Common pitfall: Do not turn a provisional location category into a definitive disease label. New pain, syncope, or instability changes the urgency even while serial testing remains incomplete.
37.Which findings support urgent torsion assessment despite preserved Doppler flow?
Adnexal torsion compromises ovarian or tubal circulation. Sudden unilateral abdominal pain, often intermittent, with nausea and vomiting is a concerning adolescent presentation, even without a known mass. Detectable Doppler flow cannot exclude torsion because twisting and vascular compromise can be incomplete or intermittent. ACOG advises against using Doppler flow alone to decide whether to operate. Persistent clinical suspicion warrants timely surgical evaluation; torsion remains a surgical diagnosis.
Apply it
An adolescent has abrupt unilateral pelvic pain, repeated vomiting, and an enlarged ovary with preserved arterial flow. Continue timely surgical assessment rather than discharging her based on the flow signal or temporary pain improvement.
Common pitfall: Neither a pain-free interval nor preserved arterial flow is a reliable exclusion. Waiting for complete flow loss can delay treatment until compromise is more advanced.
ACOG Committee Opinion No. 783: Adnexal Torsion in Adolescents
38.How should pooled cancer-risk evidence be explained during EIN counseling?
ACOG's evidence appendix reports pooled concurrent endometrial cancer prevalence of 32.6%, with a 95% confidence interval of 24.1%–42.4%, among studied patients with atypical hyperplasia. This describes cancer already present, not the future annual progression rate. Explain the estimate as roughly 33 of 100 comparable patients, while acknowledging uncertainty and differences between the studied population and the individual. A confidence interval concerns uncertainty in the population estimate; it is not a diagnostic test or proof that a particular patient has cancer.
Apply it
A patient asks whether a 32.6% estimate means she will develop cancer next year. Explain that it concerns concurrent cancer, discuss why further sampling matters, and ask her to describe that distinction in her own words before comparing treatment options.
Common pitfall: Do not equate prevalence with incidence, present a pooled estimate as an individualized prediction, or use numerical risk to override a capable patient's informed preferences.
aog_142_3_2023_08_04_amer_23-1154_sdc4.pdf · ACOG Committee Opinion No. 819: Informed Consent and Shared Decision Making
39.Why is ovarian preservation favored during adolescent detorsion?
ACOG recommends minimally invasive detorsion and preservation of adnexal structures in adolescents regardless of the ovary's initial appearance. A dark or congested ovary does not reliably establish irreversible loss of function, and reperfusion can permit recovery. Removal should be avoided unless unavoidable, such as when severely compromised tissue falls apart. This approach protects future endocrine and reproductive potential while recognizing that operative findings, tissue integrity, and technical safety still determine what can be preserved.
Apply it
Laparoscopy confirms torsion in an adolescent, and the ovary looks blue-black but remains structurally intact. Detorse and preserve it when feasible rather than performing oophorectomy solely because the initial color suggests severe venous congestion.
Common pitfall: Visual discoloration alone is an unreliable viability test. Do not allow concern about an alarming appearance to replace the recommended attempt at preservation when tissue integrity permits.
ACOG Committee Opinion No. 783: Adnexal Torsion in Adolescents
40.Why is hysterectomy definitive treatment for EIN or atypical hyperplasia?
Endometrial intraepithelial neoplasia and atypical endometrial hyperplasia are precursor lesions with a clinically important possibility of concurrent endometrial carcinoma. ACOG identifies hysterectomy as definitive treatment because it removes the affected endometrium and permits evaluation of the uterine specimen. Before conservative treatment is chosen, concurrent cancer should be actively excluded as far as possible. Endometrial ablation is inappropriate because it does not provide equivalent definitive treatment and can complicate subsequent evaluation.
Apply it
A patient with confirmed EIN has completed childbearing and is an appropriate surgical candidate. Discuss hysterectomy as definitive treatment, including the need to assess for concurrent cancer, rather than offering ablation as an equivalent less invasive substitute.
Common pitfall: Do not interpret a precursor diagnosis as proof that cancer is absent. Symptom improvement after a procedure does not establish adequate treatment of the underlying premalignant lesion.
ACOG Clinical Consensus No. 5: Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia · aog_142_3_2023_08_04_amer_23-1154_sdc4.pdf
Office Practiceapproximately 33%
41.When should pelvic inflammatory disease be treated presumptively?
CDC recommends a low clinical threshold for presumptive pelvic inflammatory disease treatment in a sexually active patient at risk for STIs who has pelvic or lower abdominal pain, no better identified cause, and cervical motion, uterine, or adnexal tenderness. Requiring all three tenderness findings reduces sensitivity and can delay treatment. Fever and a positive cervical infection test can increase diagnostic confidence but are not mandatory. Early treatment matters because mild or subtle upper-tract infection can still damage reproductive function.
Apply it
A young sexually active patient has pelvic pain and cervical motion tenderness, with no alternative explanation identified. Begin appropriate presumptive PID treatment while completing evaluation rather than waiting for fever, all three tenderness findings, or a positive gonorrhea test.
Common pitfall: A negative cervical test does not exclude upper-genital-tract infection. The low treatment threshold does not remove the need to consider ectopic pregnancy or another surgical emergency.
42.Which findings support bacterial vaginosis by Amsel criteria?
Bacterial vaginosis reflects a shift in vaginal microbial composition rather than a diagnosis established by discharge color alone. Amsel diagnosis requires at least three of four findings: homogeneous thin discharge, clue cells, vaginal pH above 4.5, and a positive amine odor test. Clue cells are vaginal epithelial cells coated with bacteria. The combination of microscopy, pH, and clinical findings is more discriminating than one symptom and helps separate BV from candidiasis and other causes of vaginitis.
Apply it
A patient has thin homogeneous discharge, a vaginal pH of 5.2, and clue cells on microscopy, but no noticeable odor. Three Amsel criteria are present, so absence of an odor complaint does not prevent a clinical BV diagnosis.
Common pitfall: An elevated pH alone is nonspecific. Do not diagnose BV solely from odor, and do not require all four Amsel findings when three are sufficient.
43.How do microscopy and pH support vulvovaginal candidiasis?
Vulvovaginal candidiasis commonly causes itching, soreness, external dysuria, and vulvar inflammation, but symptoms alone are not specific. CDC guidance supports diagnosis when compatible symptoms accompany yeast forms, hyphae, or pseudohyphae on microscopy or a positive appropriate test. Vaginal pH is usually normal, below 4.5. A negative wet mount does not exclude infection when symptoms persist; culture can clarify the diagnosis. Asymptomatic Candida colonization alone is not an indication for treatment.
Apply it
A patient with vulvar itching and erythema has a pH of 4.2 and budding yeast on microscopy. These findings support candidiasis more strongly than BV, while the symptoms distinguish active disease from an incidental positive culture without complaints.
Common pitfall: Do not treat every positive Candida test as symptomatic infection. Conversely, a negative office wet mount may need further testing when the clinical findings remain convincing.
44.Why does migraine with aura change contraceptive eligibility?
CDC U.S. MEC classifies combined hormonal contraception as category 4 for migraine with aura because the associated ischemic stroke risk makes estrogen-containing methods unacceptable in this setting. The classification applies to combined pills, patches, and vaginal rings. Establish whether the neurologic symptoms represent aura rather than treating all headaches identically. A young age or nonsmoking status does not remove this contraindication. Contraceptive counseling should consider suitable alternatives that do not contain estrogen.
Apply it
A healthy nonsmoking patient requests a combined vaginal ring but describes recurrent visual aura before migraines. Explain that changing the delivery route does not eliminate the estrogen-related eligibility issue and discuss an appropriate alternative without combined hormonal exposure.
Common pitfall: Do not interpret absence of smoking or hypertension as permission to ignore aura. A combined patch or ring is not a way around the combined-pill contraindication.
45.When should an infertility evaluation begin?
ASRM recommends evaluation after 12 months of regular unprotected intercourse for patients younger than 35 and after six months for those 35 or older. More immediate evaluation may be warranted after age 40 or with a known infertility-associated condition, such as irregular cycles or suspected tubal disease. Evaluate relevant partners concurrently. Assessment addresses ovulation, reproductive anatomy and tubal patency, and semen factors. Hysterosalpingography evaluates tubal patency and cavity contour; saline infusion sonography better delineates many intracavitary lesions.
Apply it
A 37-year-old with regular cycles has tried to conceive for seven months. Begin evaluation now, including partner assessment and appropriate anatomic assessment, rather than applying a 12-month delay or ordering ovarian reserve testing alone.
Common pitfall: The waiting period is not mandatory when a known infertility-associated condition is present. One normal test cannot exclude ovulatory, tubal, uterine, and partner factors simultaneously.
ASRM: Fertility Evaluation of Infertile Women—Committee Opinion, 2021
46.When should progesterone be measured to assess ovulation?
When biochemical confirmation of ovulation is needed, ASRM recommends measuring serum progesterone approximately one week before the expected next menstrual period rather than automatically on cycle day 21. A properly timed value can provide evidence of recent ovulation. Progesterone secretion fluctuates substantially, so a single measurement cannot reliably characterize luteal-phase quality. Interpret the result in relation to the patient's cycle length, clinical history, and reason for testing instead of treating one calendar day as universally correct.
Apply it
A patient consistently has 35-day cycles, and confirmation of ovulation is needed. Schedule progesterone approximately on day 28, one week before the expected next period, rather than ordering a routine day-21 sample that could be mistimed.
Common pitfall: A low result from an incorrectly timed sample can falsely suggest anovulation. One progesterone measurement supports recent ovulation but does not grade the entire luteal phase.
ASRM: Fertility Evaluation of Infertile Women—Committee Opinion, 2021
47.What can ovarian reserve testing actually predict?
Ovarian reserve tests estimate aspects of the remaining follicular pool and help anticipate response to ovarian stimulation. ASRM cautions that they do not function as a definitive fertility test or reliably establish whether an individual can conceive without treatment. Age and the complete clinical context remain central. A low anti-Müllerian hormone result does not prove sterility, while a reassuring result does not neutralize age-related reproductive decline or exclude tubal, ovulatory, uterine, or partner factors.
Apply it
A patient with a low anti-Müllerian hormone result assumes spontaneous pregnancy is impossible. Explain the test's role in estimating stimulation response and integrate age, cycle history, exposure to pregnancy, and other fertility factors before drawing conclusions about her options.
Common pitfall: Do not translate a low reserve marker into zero pregnancy potential. A normal marker is equally unsuitable as a guarantee of future fertility or permission to ignore age.
ASRM: Fertility Evaluation of Infertile Women—Committee Opinion, 2021
48.When should family history lead to BRCA genetic counseling?
The USPSTF recommends a brief familial risk assessment for patients with relevant personal or family histories of breast, ovarian, tubal, or peritoneal cancer, or ancestry associated with BRCA mutations. A positive assessment should lead to genetic counseling and testing when indicated after counseling. General breast-cancer risk tools are not substitutes for tools designed to identify inherited BRCA risk. Counseling clarifies the pedigree, implications, limitations, and most informative testing strategy before a result is pursued.
Apply it
A patient reports ovarian cancer in her mother and early breast cancer in a close relative. Use an appropriate familial risk tool and arrange genetic counseling after a positive result rather than treating routine breast screening as a complete response.
Common pitfall: Do not use absence of a current cancer diagnosis to dismiss inherited risk. A positive brief assessment indicates need for counseling, not automatic proof of a pathogenic variant.
USPSTF: BRCA-Related Cancer—Risk Assessment, Genetic Counseling, and Genetic Testing
49.When should average-risk colorectal cancer screening begin?
The USPSTF recommends colorectal cancer screening beginning at age 45 for average-risk adults, with routine screening through age 75 and selective decisions from 76 to 85. Several stool-based and direct-visualization strategies are acceptable when their required follow-up can be completed. This recommendation concerns asymptomatic screening. Rectal bleeding, iron-deficiency anemia, or another concerning symptom requires diagnostic evaluation, while hereditary syndromes and certain personal histories require a different risk-based approach rather than automatic application of average-risk scheduling.
Apply it
An asymptomatic 46-year-old with no relevant personal or family history has never been screened. Offer an appropriate colorectal screening strategy now rather than waiting until age 50, and explain what follow-up a positive screening result would require.
Common pitfall: Do not confuse an abnormal screening test with a completed evaluation. Symptoms and high-risk histories can require diagnostic or intensified assessment outside average-risk screening recommendations.
50.Which patients should receive osteoporosis screening?
The USPSTF recommends osteoporosis screening for women 65 years or older and for postmenopausal women younger than 65 who are at increased fracture risk after clinical risk assessment. Dual-energy x-ray absorptiometry measures bone mineral density and can be used with fracture-risk assessment. Menopause alone does not mean every younger patient requires immediate DXA. Distinguish preventive screening from evaluation of an existing fragility fracture or a secondary cause of bone loss, which raises a separate diagnostic question.
Apply it
A 67-year-old without fractures asks whether bone testing is necessary because she feels well. Offer osteoporosis screening, explaining that low bone density can be silent and that absence of symptoms does not remove the age-based screening indication.
Common pitfall: Do not require pain or a previous fracture before screening an eligible patient. In younger postmenopausal patients, use risk assessment rather than menopause alone as the deciding criterion.
51.Who needs routine chlamydia screening?
CDC recommends annual chlamydia screening for sexually active women younger than 25 and for older women with increased risk, such as a new partner, multiple partners, or a partner with an STI. Screening is useful because infection is often asymptomatic and can contribute to upper-genital-tract complications. Symptoms instead prompt diagnostic evaluation and appropriate treatment assessment. Age-based screening eligibility is independent of whether a patient currently requests contraception or undergoes cervical cancer screening.
Apply it
A sexually active 22-year-old attending a preventive visit reports no discharge or pelvic pain. Offer annual chlamydia screening despite the absence of symptoms; her eligibility does not depend on a Pap test being due at the same visit.
Common pitfall: A symptom-free history does not exclude chlamydia. Do not use cervical cancer screening intervals to determine STI screening frequency or assume older patients never need risk-based testing.
52.When can a copper IUD provide emergency contraception?
CDC U.S. SPR permits copper IUD placement within five days of the first act of unprotected intercourse for emergency contraception. When ovulation can be estimated, placement may occur more than five days after intercourse if it is no more than five days after ovulation. The device also provides ongoing contraception. The decision requires appropriate assessment of pregnancy possibility and IUD eligibility. Emergency use and future contraceptive benefit should both be discussed when selecting among available methods.
Apply it
A patient presents four days after unprotected intercourse and wants highly effective emergency contraception plus an ongoing method. If eligible, offer a copper IUD, explaining that placement addresses the recent exposure and provides continued contraception after the visit.
Common pitfall: Do not assume every emergency contraceptive method has the same timing rules. The ovulation-based extension requires a reasonable estimate, not an unsupported guess about cycle timing.
53.How should contraception restart and backup protection be managed after ulipristal?
Ulipristal acts at progesterone receptors; early progestin exposure can reduce its ovulation-delaying effect. After ulipristal, wait at least five days before restarting a combined pill. Use condoms or abstain during the delay and for seven days after restarting, or until the next menses, whichever occurs first. Test for pregnancy if no withdrawal bleed occurs within three weeks. For methods requiring a clinician visit, such as an implant, DMPA, or hormonal IUD, CDC allows individualized consideration of same-visit initiation after weighing interaction risk against failure to initiate ongoing contraception.
Apply it
A patient takes ulipristal today and wants to resume her combined pill tonight. Explain the five-day delay, subsequent seven-day backup interval or earlier next menses, and three-week pregnancy-test trigger. After levonorgestrel emergency contraception, hormonal contraception can start immediately, with seven days of backup.
Common pitfall: Emergency pills do not protect later intercourse. The individualized same-visit consideration for clinician-administered methods does not make immediate combined-pill restart the routine recommendation after ulipristal.
54.Which influenza vaccine approach is appropriate during pregnancy?
CDC recommends an age-appropriate inactivated or recombinant influenza vaccine during pregnancy; it can be administered in any trimester. The live attenuated intranasal influenza vaccine is contraindicated during pregnancy. The distinction concerns vaccine platform rather than a rule to avoid all vaccination during fetal development. Maternal vaccination reduces influenza-related risk and can provide passive protection to the infant. Review the actual product rather than assuming that every influenza vaccine offered in a clinic is interchangeable.
Apply it
A pregnant patient in her first trimester is offered either an injectable inactivated influenza vaccine or an intranasal live vaccine. Recommend the appropriate injectable product rather than delaying vaccination solely because she has not reached the second trimester.
Common pitfall: Do not generalize the live-vaccine contraindication to inactivated influenza vaccination. A first-trimester pregnancy is not, by itself, a reason to postpone an otherwise indicated influenza vaccine.
55.What makes fertility-preserving EIN treatment an active surveillance plan?
For EIN or atypical hyperplasia when hysterectomy is deferred or unsuitable, ACOG recommends progestin treatment after efforts to exclude concurrent carcinoma, with close histologic surveillance. Repeat endometrial assessment within three to six months evaluates regression, persistence, or progression. Reduced bleeding does not establish lesion clearance. Counseling must address recurrence, progression, and the possibility that conservative treatment will become inappropriate. Observation without treatment is not an adequate fertility-preserving strategy.
Apply it
A patient choosing fertility preservation reports amenorrhea after four months of progestin therapy. Perform the planned repeat histologic assessment rather than declaring remission from symptom improvement.
Common pitfall: Fertility preservation does not mean indefinite avoidance of sampling or surgery. Establish the reassessment plan before starting treatment and use histology, not symptoms alone, to assess response.
ACOG Clinical Consensus No. 5: Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia · aog_142_3_2023_08_04_amer_23-1154_sdc4.pdf
56.When does office hypertension require medication as well as lifestyle treatment?
For nonpregnant adults, the 2025 AHA/ACC guideline recommends medication plus lifestyle treatment for average systolic pressure at least 140 mm Hg or diastolic pressure at least 90 mm Hg. At average pressure at least 130/80 mm Hg, medication is also recommended for patients with clinical cardiovascular disease, previous stroke, diabetes, chronic kidney disease, or a 10-year PREVENT cardiovascular risk of at least 7.5%. Patients below that risk threshold without those conditions can initially use lifestyle treatment for three to six months; persistent average pressure at least 130/80 then warrants medication. For stage-2 hypertension, initial treatment with two first-line agents from different classes is preferred, ideally in a single combination pill. Confirm the average using accurate repeated measurements and home monitoring. See the [2025 AHA/ACC guideline summary](https://professional.heart.org/en/science-news/2025-high-blood-pressure-guideline/top-things-to-know).
Apply it
A nonpregnant patient with confirmed averages of 146/92 mm Hg has stage-2 hypertension. Begin lifestyle measures and two first-line agents from different classes, preferably in one combination pill when appropriate. A patient averaging 134/84 with a 10-year PREVENT risk of 8% also warrants medication alongside lifestyle treatment rather than an initial lifestyle-only trial.
Common pitfall: Feeling well does not remove the treatment indication. Do not substitute an unspecified risk estimate for the PREVENT calculator and its 7.5% threshold. A single office reading does not establish the usual average, and pregnancy hypertension requires its own treatment framework.
57.How can history distinguish stress from urgency incontinence?
Stress urinary incontinence is leakage associated with exertion, coughing, or sneezing; urgency incontinence accompanies a sudden compelling desire to void that is difficult to defer. Both can coexist as mixed symptoms. EAU guidance supports structured history, examination, urinalysis, bladder diaries, and assessment of emptying as appropriate. A symptom label should reflect the circumstances of leakage rather than frequency alone. Initial evaluation also seeks pain, hematuria, infection, or other features requiring a different diagnostic pathway.
Apply it
A patient leaks when coughing and also sometimes loses urine while rushing to the toilet after sudden urgency. Recognize a mixed symptom pattern and assess both components rather than forcing all episodes into a single category from the word leakage.
Common pitfall: Frequency alone does not establish urgency incontinence, and leakage does not exclude incomplete emptying. A bladder diary can reveal distinctions that a general complaint of accidents misses.
EAU Guidelines on Non-neurogenic Female Lower Urinary Tract Symptoms: Diagnosis
58.How should a new diabetes-range A1C change office care?
An A1C of at least 6.5% is in the diabetes range; without clear symptoms, confirm with repeat A1C or another diagnostic glucose test. Once diabetes is established, management includes nutrition, physical activity, individualized glucose-lowering treatment, and attention to blood pressure, lipids, and smoking. An A1C below 7% is a common goal for many nonpregnant adults, but comorbidity and hypoglycemia risk modify targets. See [NIDDK: A1C testing](https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test) and [Managing Diabetes](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes).
Apply it
An asymptomatic nonpregnant patient has A1C 6.8%. Arrange confirmation and begin counseling. If confirmed, establish a treatment and monitoring plan rather than waiting for symptoms or addressing glucose while overlooking cardiovascular risk.
Common pitfall: A diagnostic threshold is not the same as an individualized treatment target. A1C reflects longer-term glycemia and does not replace assessment of current symptoms or short-term glucose changes.
59.When does PID warrant hospitalization rather than outpatient treatment?
CDC hospitalization considerations for pelvic inflammatory disease include pregnancy, tubo-ovarian abscess, severe illness or vomiting, inability to tolerate or follow an outpatient regimen, inability to exclude a surgical emergency, or failure to respond to outpatient treatment. Outpatients should show clinical improvement within 72 hours, including reduced abdominal and pelvic tenderness and resolution of fever when initially present. Failure to improve within 72 hours after outpatient treatment warrants hospitalization, reassessment of the antimicrobial regimen, and additional evaluation for alternative diagnoses. Outpatient suitability therefore depends on severity, diagnostic confidence, ability to take medication, and access to timely reassessment.
Apply it
A patient treated as an outpatient returns after 72 hours with unchanged pelvic pain and tenderness. Arrange hospitalization, review the antimicrobial regimen, and investigate alternatives such as appendicitis or a tubo-ovarian abscess. A patient who cannot retain oral medication because of persistent vomiting warrants inpatient assessment immediately; the 72-hour interval is not a reason to delay escalation.
Common pitfall: Normal blood pressure and modest pelvic tenderness do not establish outpatient suitability. Document the expected improvement and reassessment interval. Clinical worsening requires earlier evaluation, while lack of improvement by 72 hours requires escalation even without dramatic vital-sign abnormalities.
60.When should hysteroscopy with endometrial sampling follow an office biopsy?
A working diagnosis of EIN or atypical hyperplasia requires assessment for concurrent carcinoma before conservative treatment. ACOG identifies hysteroscopic examination with further endometrial sampling as the most accurate approach. Direct visualization helps identify focal lesions for targeted sampling, while background endometrium also needs assessment. Obtain tissue suitable for histology; a reassuring visual impression alone cannot exclude carcinoma. Office suitability depends on patient tolerance, procedural needs, and ability to obtain an adequate specimen.
Apply it
An office biopsy shows EIN, and the patient requests fertility preservation. Arrange hysteroscopic assessment with further sampling before committing to conservative therapy. If a focal lesion is seen, include it in the specimen rather than relying only on a blind sample.
Common pitfall: A precursor finding on a small biopsy does not establish that the entire cavity is free of carcinoma. Neither normal appearance nor inadequate tissue provides a reliable histologic exclusion.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give all three official domains substantial study time; each contributes approximately one third of the examination. Use the official outline to track subtopic gaps rather than relying on equal counts.
- Emphasize intrapartum decisions: contraction adequacy, active-phase arrest, induction after membrane rupture, pushing progress, operative vaginal candidacy, and abnormal fetal monitoring.
- Distinguish prevention from emergency treatment in hypertensive disease, and connect growth-restriction Doppler patterns to surveillance and delivery timing.
- For surgical complications, identify the threatened function and decisive cue: hemorrhage, torsion, urinary leakage, incomplete emptying, bowel injury, pulmonary embolism, or fluid toxicity.
- In Office Practice, match contraception, screening, infertility evaluation, hypertension care, diabetes assessment, and endometrial procedures to the patient's risks and goals.
- Practise explaining absolute risks, study uncertainty, test limitations, and informed choices. Continue studying additional blueprint topics, including menopause, menstrual disorders, operative breadth, handoffs, error disclosure, and quality improvement.
A practical preparation plan
1. Map the full outline
Read the official Specialty Blueprint and mark each topic as secure, uncertain, or unstudied. Use these 60 selected concepts as decision anchors while retaining the outline as the complete scope.
2. Build threshold comparisons
Compare four versus six hours of labor-arrest criteria, quantitative contraction adequacy, induction after membrane rupture, short-cervix thresholds, fetal Doppler delivery ranges, and fertility evaluation by age. Record qualifying conditions beside every number.
3. Rehearse emergency mechanisms
For each vignette, state the threatened function, decisive cue, and corrective action. Compare severe hypertension with prophylaxis, persistent category III monitoring with labor arrest, stable ectopic treatment with rupture, and expected recovery with bowel injury or pulmonary embolism.
4. Use prevention and procedure matrices
Compare eligibility, timing, exclusions, and follow-up for aspirin, folic acid, GBS prophylaxis, Rh(D) immune globulin, contraception, methotrexate, surgical antibiotics, and endometrial sampling. Include the duration of backup contraception and the endpoint of monitoring.
5. Complete the independent question set
Answer all 20 questions before reading explanations. Classify errors as missed clinical cues, wrong thresholds, unsupported assumptions, or confusion between diagnostic and preventive care. Review every distractor rationale, including questions answered correctly.
6. Close gaps through active recall and communication
Use the 20 flashcards without viewing their backs. Rehearse explaining the difference between concurrent cancer prevalence and future progression risk, then check understanding through teach-back. Return to uncovered blueprint topics rather than treating this small set as a passing-score estimate.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- 2026 Specialty Qualifying Examination Bulletin
- Specialty Blueprint
- ABOG 2025 Annual Report, page 49
- ABOG 2024 Annual Report, pages 33–34
- ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management
- USPSTF: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
- ACOG–SMFM Obstetric Care Consensus No. 7: Placenta Accreta Spectrum
- WHO: Bleeding After Birth—Provider Guide
- SMFM Consult Series No. 70: Management of Short Cervix Without Previous Spontaneous Preterm Birth
- USPSTF: Gestational Diabetes—Screening
- SMFM Consult Series No. 52: Diagnosis and Management of Fetal Growth Restriction
- ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy
- ACOG Committee Opinion No. 783: Adnexal Torsion in Adolescents
- ACOG Committee Opinion No. 701: Choosing the Route of Hysterectomy for Benign Disease
- EAU Guidelines on Urological Trauma
- BSGE/ESGE Guideline on Management of Fluid Distension Media in Operative Hysteroscopy
- ACOG Committee Opinion No. 819: Informed Consent and Shared Decision Making
- CDC Guideline for the Prevention of Surgical Site Infection, 2017
- CDC STI Treatment Guidelines: Pelvic Inflammatory Disease
- CDC STI Treatment Guidelines: Bacterial Vaginosis
- CDC U.S. MEC 2024: Combined Hormonal Contraceptives
- ASRM: Fertility Evaluation of Infertile Women—Committee Opinion, 2021
- USPSTF: BRCA-Related Cancer—Risk Assessment, Genetic Counseling, and Genetic Testing
- USPSTF: Colorectal Cancer—Screening
- USPSTF: Folic Acid Supplementation to Prevent Neural Tube Defects
- CDC STI Treatment Guidelines: Syphilis During Pregnancy
- CDC: Guidelines for Vaccinating Pregnant Women
- ACOG Committee Opinion No. 797: Prevention of Group B Streptococcal Early-Onset Disease in Newborns
- FDA: RhoGAM and MICRhoGAM Package Insert
- ACOG Committee Opinion No. 750: Perioperative Pathways—Enhanced Recovery After Surgery
- ACOG Clinical Consensus No. 5: Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia
- EAU Guidelines on Non-neurogenic Female Lower Urinary Tract Symptoms: Diagnosis
- CDC: STI Screening Recommendations
- CDC U.S. MEC: Lactational Amenorrhea Method
- CDC U.S. SPR: Emergency Contraception
- CDC STI Treatment Guidelines: Vulvovaginal Candidiasis
- USPSTF: Osteoporosis to Prevent Fractures—Screening
- ASHP/IDSA/SIS/SHEA: Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery
- DailyMed - TRANEXAMIC ACID injection, solution
- Ectopic-Pregnancy-ACOG.pdf
- aog_142_3_2023_08_04_amer_23-1154_sdc4.pdf
- Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf
- acog_clinical_practice_guideline_no_.22.pdf
- Laparoscopy – recovering well | RCOG
- The A1C Test & Diabetes - NIDDK
- Managing Diabetes - NIDDK
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.